Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress
21 Agosto 2024 - 2:30PM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing precision
nerve-targeted treatments, today announced its technology and
interim clinical trial findings will be featured in a podium
presentation at the 2024 Cardiovascular and Interventional
Radiological Society of Europe (CIRSE) Annual Congress being held
September 14-18, 2024 in Lisbon, Portugal.
“As we continue to execute on our clinical
strategy, engaging with the scientific community is a priority and
area of focus for Autonomix. We are thrilled to have received
acceptance for presentation at this prestigious global congress and
to be included in CIRSE’s newly added, state-of-the art interactive
area, called SPHAIRE, which is dedicated to deepening the
understanding of what emerging technologies can bring to
Interventional Radiology. We believe aligning the release of our
data and our publication strategy is a key component of raising
awareness for our innovative platform technology, and we look
forward to participating in this upcoming event,” commented Brad
Hauser, Chief Executive Officer of Autonomix.
Details of the presentation are as follows:
Title: Rethinking pain management: transforming
patient outcomes with precision mapping technology and celiac nerve
RF ablation in end stage cancerSession: Future AI
Applications in Interventional RadiologyPresenter:
Dr. Askar Sabirov, Primary Investigator for the Company’s ongoing
PoC human clinical trial in pain associated with pancreatic
cancerSession Date and Time: Monday, September
16th from 11:15 AM – 12:15 PM ET
For more information about the CIRSE Annual
Congress, please visit the event website here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that can detect and
differentiate neural signals with approximately 3,000 times greater
sensitivity than currently available technologies. We believe this
will enable, for the first time ever, transvascular diagnosis and
treatment of diseases involving the peripheral nervous system
virtually anywhere in the body.
We are initially developing this technology for
the treatment of pain, with initial trials focused on pancreatic
cancer, a condition that causes debilitating pain and is without a
reliable solution. Our technology constitutes a platform to address
dozens of indications, including cardiology, hypertension and
chronic pain management, across a wide disease spectrum. Our
technology is investigational and has not yet been cleared for
marketing in the United States.
For more information,
visit autonomix.com and connect with the Company
on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Such forward-looking statements can be identified by
the use of words such as “should,” “might,” “may,” “intends,”
“anticipates,” “believes,” “estimates,” “projects,” “forecasts,”
“expects,” “plans,” “can,” and “proposes.”
Although Autonomix believes that the
expectations reflected in these forward-looking statements are
based on reasonable assumptions, there are a number of risks and
uncertainties that could cause actual results to differ materially
from such forward-looking statements. You are urged to carefully
review and consider any cautionary statements and other
disclosures, including the statements made under the heading “Risk
Factors” and elsewhere in the Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (“SEC”) on May 31,
2024. Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Autonomix Medical (NASDAQ:AMIX)
Storico
Da Dic 2023 a Dic 2024